{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T13:19:26Z","timestamp":1789305566857,"version":"build-2803163510"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1038\/s41375-025-02652-0","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T04:01:02Z","timestamp":1748404862000},"page":"1948-1959","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["T cell receptor mimic CAR T cells targeting cathepsin G signal peptide"],"prefix":"10.1038","volume":"39","author":[{"given":"Jun","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhua","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guojun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Torikai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pariya","family":"Sukhumalchandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaohua","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Kerros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Philips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy E.","family":"Lofton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason K.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A.","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sathvik","family":"Patchametla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sergeeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"St. John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongxing","family":"Zha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1196-1715","authenticated-orcid":false,"given":"Jeffrey","family":"Molldrem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7648-4377","authenticated-orcid":false,"given":"Gheath","family":"Alatrash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,28]]},"reference":[{"key":"2652_CR1","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/35077251","volume":"411","author":"FR Appelbaum","year":"2001","unstructured":"Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Nature. 2001;411:385\u20139.","journal-title":"Nature"},{"key":"2652_CR2","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1158\/2326-6066.CIR-18-0307","volume":"7","author":"SH Baumeister","year":"2019","unstructured":"Baumeister SH, Murad J, Werner L, Daley H, Trebeden-Negre H, Gicobi JK, et al. Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML\/MDS and multiple myeloma. Cancer Immunol Res. 2019;7:100\u201312.","journal-title":"Cancer Immunol Res"},{"key":"2652_CR3","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1038\/s41375-021-01232-2","volume":"35","author":"FP Tambaro","year":"2021","unstructured":"Tambaro FP, Singh H, Jones E, Rytting M, Mahadeo KM, Thompson P, et al. Autologous CD33-CAR-T cells for treatment of relapsed\/refractory acute myelogenous leukemia. Leukemia. 2021;35:3282\u20136.","journal-title":"Leukemia"},{"key":"2652_CR4","doi-asserted-by":"publisher","first-page":"3145","DOI":"10.1182\/blood.2020009759","volume":"137","author":"M Wermke","year":"2021","unstructured":"Wermke M, Kraus S, Ehninger A, Bargou RC, Goebeler ME, Middeke JM, et al. Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed\/refractory AML. Blood. 2021;137:3145\u20138.","journal-title":"Blood"},{"key":"2652_CR5","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1038\/s41375-022-01703-0","volume":"36","author":"H Zhang","year":"2022","unstructured":"Zhang H, Bu C, Peng Z, Li G, Zhou Z, Ding W, et al. Characteristics of anti-CLL1 based CAR-T therapy for children with relapsed or refractory acute myeloid leukemia: the multi-center efficacy and safety interim analysis. Leukemia. 2022;36:2596\u2013604.","journal-title":"Leukemia"},{"key":"2652_CR6","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1158\/1078-0432.CCR-12-2753","volume":"19","author":"M Zhang","year":"2013","unstructured":"Zhang M, Sukhumalchandra P, Enyenihi AA, St John LS, Hunsucker SA, et al. A novel HLA-A*0201 restricted peptide derived from cathepsin G is an effective immunotherapeutic target in acute myeloid leukemia. Clin Cancer Res. 2013;19:247\u201357.","journal-title":"Clin Cancer Res"},{"key":"2652_CR7","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/leu.2016.249","volume":"31","author":"G Alatrash","year":"2017","unstructured":"Alatrash G, Garber HR, Zhang M, Sukhumalchandra P, Qiu Y, Jakher H, et al. Cathepsin G is broadly expressed in acute myeloid leukemia and is an effective immunotherapeutic target. Leukemia. 2017;31:234\u20137.","journal-title":"Leukemia"},{"key":"2652_CR8","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1126\/science.1546329","volume":"255","author":"RA Henderson","year":"1992","unstructured":"Henderson RA, Michel H, Sakaguchi K, Shabanowitz J, Appella E, Hunt DF, et al. HLA-A2.1-associated peptides from a mutant cell line: a second pathway of antigen presentation. Science. 1992;255:1264\u20136.","journal-title":"Science"},{"key":"2652_CR9","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/356443a0","volume":"356","author":"ML Wei","year":"1992","unstructured":"Wei ML, Cresswell P. HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides. Nature. 1992;356:443\u20136.","journal-title":"Nature"},{"key":"2652_CR10","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1002\/eji.200838136","volume":"38","author":"AO Weinzierl","year":"2008","unstructured":"Weinzierl AO, Rudolf D, Hillen N, Tenzer S, van Endert P, Schild H, et al. Features of TAP-independent MHC class I ligands revealed by quantitative mass spectrometry. Eur J Immunol. 2008;38:1503\u201310.","journal-title":"Eur J Immunol"},{"key":"2652_CR11","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1038\/s41375-025-02520-x","volume":"39","author":"C Shi","year":"2025","unstructured":"Shi C, Tian Z, Yan J, Zhang M, Sukhumalchandra P, Chang E, et al. Immunotherapy targeting a leader sequence cathepsin G-derived peptide. Leukemia. 2025;39:888\u201398.","journal-title":"Leukemia"},{"key":"2652_CR12","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1182\/blood.V89.10.3503","volume":"89","author":"N Borregaard","year":"1997","unstructured":"Borregaard N, Cowland JB. Granules of the human neutrophilic polymorphonuclear leukocyte. Blood. 1997;89:3503\u201321.","journal-title":"Blood"},{"key":"2652_CR13","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.3389\/fimmu.2017.01975","volume":"8","author":"M Khan","year":"2017","unstructured":"Khan M, Carmona S, Sukhumalchandra P, Roszik J, Philips A, Perakis AA, et al. Cathepsin G is expressed by acute lymphoblastic leukemia and is a potential immunotherapeutic target. Front Immunol. 2017;8:1975.","journal-title":"Front Immunol"},{"key":"2652_CR14","doi-asserted-by":"publisher","first-page":"4495","DOI":"10.1158\/1078-0432.CCR-04-2363","volume":"11","author":"H Fujiwara","year":"2005","unstructured":"Fujiwara H, Melenhorst JJ, El Ouriaghli F, Kajigaya S, Grube M, Sconocchia G, et al. In vitro induction of myeloid leukemia-specific CD4 and CD8 T cells by CD40 ligand-activated B cells gene modified to express primary granule proteins. Clin Cancer Res. 2005;11:4495\u2013503.","journal-title":"Clin Cancer Res"},{"key":"2652_CR15","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.ab.2012.01.033","volume":"423","author":"E Gorodkiewicz","year":"2012","unstructured":"Gorodkiewicz E, Sienczyk M, Regulska E, Grzywa R, Pietrusewicz E, Lesner A, et al. Surface plasmon resonance imaging biosensor for cathepsin G based on a potent inhibitor: development and applications. Anal Biochem. 2012;423:218\u201323.","journal-title":"Anal Biochem"},{"key":"2652_CR16","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1136\/jcp.40.6.699-b","volume":"40","author":"J Crocker","year":"1987","unstructured":"Crocker J, Skilbeck N. Granulocyte markers cathepsin G and leukocyte elastase are rarely observed in Reed-Sternberg and Hodgkin\u2019s cells. J Clin Pathol. 1987;40:699\u2013700.","journal-title":"J Clin Pathol"},{"key":"2652_CR17","doi-asserted-by":"publisher","first-page":"35341","DOI":"10.1074\/jbc.M112.385617","volume":"287","author":"AD Gregory","year":"2012","unstructured":"Gregory AD, Hale P, Perlmutter DH, Houghton AM. Clathrin pit-mediated endocytosis of neutrophil elastase and cathepsin G by cancer cells. J Biol Chem. 2012;287:35341\u201350.","journal-title":"J Biol Chem"},{"key":"2652_CR18","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1158\/1078-0432.CCR-18-1527","volume":"25","author":"G Alatrash","year":"2019","unstructured":"Alatrash G, Qiao N, Zhang M, Zope M, Perakis AA, Sukhumalchandra P, et al. Fucosylation enhances the efficacy of adoptively transferred antigen-specific cytotoxic T lymphocytes. Clin Cancer Res. 2019;25:2610\u201320.","journal-title":"Clin Cancer Res"},{"key":"2652_CR19","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1038\/leu.2016.57","volume":"30","author":"A Sergeeva","year":"2016","unstructured":"Sergeeva A, He H, Ruisaard K, St John L, Alatrash G, Clise-Dwyer K, et al. Activity of 8F4, a T-cell receptor-like anti-PR1\/HLA-A2 antibody, against primary human AML in vivo. Leukemia. 2016;30:1475\u201384.","journal-title":"Leukemia"},{"key":"2652_CR20","doi-asserted-by":"publisher","first-page":"180","DOI":"10.4049\/jimmunol.154.1.180","volume":"154","author":"LD Shultz","year":"1995","unstructured":"Shultz LD, Schweitzer PA, Christianson SW, Gott B, Schweitzer IB, Tennent B, et al. Multiple defects in innate and adaptive immunologic function in NOD\/LtSz-scid mice. J Immunol. 1995;154:180\u201391.","journal-title":"J Immunol"},{"key":"2652_CR21","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/nm.2700","volume":"18","author":"E Provasi","year":"2012","unstructured":"Provasi E, Genovese P, Lombardo A, Magnani Z, Liu PQ, Reik A, et al. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat Med. 2012;18:807\u201315.","journal-title":"Nat Med"},{"key":"2652_CR22","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439\u201348.","journal-title":"N Engl J Med"},{"key":"2652_CR23","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380:1726\u201337.","journal-title":"N Engl J Med"},{"key":"2652_CR24","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1002\/cncr.31896","volume":"125","author":"P Williams","year":"2019","unstructured":"Williams P, Basu S, Garcia-Manero G, Hourigan CS, Oetjen KA, Cortes JE, et al. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer. 2019;125:1470\u201381.","journal-title":"Cancer"},{"key":"2652_CR25","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1182\/blood.2020009471","volume":"137","author":"PD Lulla","year":"2021","unstructured":"Lulla PD, Naik S, Vasileiou S, Tzannou I, Watanabe A, Kuvalekar M, et al. Clinical effects of administering leukemia-specific donor T cells to patients with AML\/MDS after allogeneic transplant. Blood. 2021;137:2585\u201397.","journal-title":"Blood"},{"key":"2652_CR26","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1182\/blood.2021014648","volume":"139","author":"S Naik","year":"2022","unstructured":"Naik S, Vasileiou S, Tzannou I, Kuvalekar M, Watanabe A, Robertson C, et al. Donor-derived multiple leukemia antigen-specific T-cell therapy to prevent relapse after transplant in patients with ALL. Blood. 2022;139:2706\u201311.","journal-title":"Blood"},{"key":"2652_CR27","doi-asserted-by":"publisher","first-page":"4938","DOI":"10.1182\/blood.V90.12.4938","volume":"90","author":"KP Papadopoulos","year":"1997","unstructured":"Papadopoulos KP, Suciu-Foca N, Hesdorffer CS, Tugulea S, Maffei A, Harris PE. Naturally processed tissue- and differentiation stage-specific autologous peptides bound by HLA class I and II molecules of chronic myeloid leukemia blasts. Blood. 1997;90:4938\u201346.","journal-title":"Blood"},{"key":"2652_CR28","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41591-019-0400-z","volume":"25","author":"C Toffalori","year":"2019","unstructured":"Toffalori C, Zito L, Gambacorta V, Riba M, Oliveira G, Bucci G, et al. Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation. Nat Med. 2019;25:603\u201311.","journal-title":"Nat Med"},{"key":"2652_CR29","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1056\/NEJMoa1808777","volume":"379","author":"MJ Christopher","year":"2018","unstructured":"Christopher MJ, Petti AA, Rettig MP, Miller CA, Chendamarai E, Duncavage EJ, et al. Immune escape of relapsed AML cells after allogeneic transplantation. N Engl J Med. 2018;379:2330\u201341.","journal-title":"N Engl J Med"},{"key":"2652_CR30","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/leu.2008.391","volume":"23","author":"S Hoves","year":"2009","unstructured":"Hoves S, Aigner M, Pfeiffer C, Laumer M, Obermann EC, Mackensen A. In situ analysis of the antigen-processing machinery in acute myeloid leukaemic blasts by tissue microarray. Leukemia. 2009;23:877\u201385.","journal-title":"Leukemia"},{"key":"2652_CR31","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","volume":"5","author":"E Sotillo","year":"2015","unstructured":"Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, Wu G, et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 2015;5:1282\u201395.","journal-title":"Cancer Discov"},{"key":"2652_CR32","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507\u201317.","journal-title":"N Engl J Med"},{"key":"2652_CR33","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ccell.2021.12.005","volume":"40","author":"S Heitzeneder","year":"2022","unstructured":"Heitzeneder S, Bosse KR, Zhu Z, Zhelev D, Majzner RG, Radosevich MT, et al. GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity. Cancer Cell. 2022;40:53\u201369.e59.","journal-title":"Cancer Cell"},{"key":"2652_CR34","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ccell.2021.12.010","volume":"40","author":"A Hotblack","year":"2022","unstructured":"Hotblack A, Straathof K. Fine-tuning CARs for best performance. Cancer Cell. 2022;40:11\u201313.","journal-title":"Cancer Cell"},{"key":"2652_CR35","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1158\/2159-8290.CD-19-0945","volume":"10","author":"RG Majzner","year":"2020","unstructured":"Majzner RG, Rietberg SP, Sotillo E, Dong R, Vachharajani VT, Labanieh L, et al. Tuning the antigen density requirement for CAR T-cell activity. Cancer Discov. 2020;10:702\u201323.","journal-title":"Cancer Discov"},{"key":"2652_CR36","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45\u201356.","journal-title":"N Engl J Med"},{"key":"2652_CR37","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"AH Long","year":"2015","unstructured":"Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015;21:581\u201390.","journal-title":"Nat Med"},{"key":"2652_CR38","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol. 2023;20:359\u201371.","journal-title":"Nat Rev Clin Oncol"},{"key":"2652_CR39","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","volume":"24","author":"JA Fraietta","year":"2018","unstructured":"Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24:563\u201371.","journal-title":"Nat Med"},{"key":"2652_CR40","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1365-2567.2011.03515.x","volume":"135","author":"JS Bridgeman","year":"2012","unstructured":"Bridgeman JS, Sewell AK, Miles JJ, Price DA, Cole DK. Structural and biophysical determinants of alphabeta T-cell antigen recognition. Immunology. 2012;135:9\u201318.","journal-title":"Immunology"},{"key":"2652_CR41","doi-asserted-by":"publisher","first-page":"5727","DOI":"10.4049\/jimmunol.178.9.5727","volume":"178","author":"DK Cole","year":"2007","unstructured":"Cole DK, Pumphrey NJ, Boulter JM, Sami M, Bell JI, Gostick E, et al. Human TCR-binding affinity is governed by MHC class restriction. J Immunol. 2007;178:5727\u201334.","journal-title":"J Immunol"},{"key":"2652_CR42","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1074\/jbc.M113.522110","volume":"289","author":"DK Cole","year":"2014","unstructured":"Cole DK, Miles KM, Madura F, Holland CJ, Schauenburg AJ, Godkin AJ, et al. T-cell receptor (TCR)-peptide specificity overrides affinity-enhancing TCR-major histocompatibility complex interactions. J Biol Chem. 2014;289:628\u201338.","journal-title":"J Biol Chem"},{"key":"2652_CR43","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/j.1600-065X.1998.tb01199.x","volume":"163","author":"SJ Davis","year":"1998","unstructured":"Davis SJ, Ikemizu S, Wild MK, van der Merwe PA. CD2 and the nature of protein interactions mediating cell-cell recognition. Immunol. Rev. 1998;163:217\u201336.","journal-title":"Immunol. Rev"},{"key":"2652_CR44","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1146\/annurev.immunol.16.1.523","volume":"16","author":"MM Davis","year":"1998","unstructured":"Davis MM, Boniface JJ, Reich Z, Lyons D, Hampl J, Arden B, et al. Ligand recognition by alpha beta T cell receptors. Annu Rev Immunol. 1998;16:523\u201344.","journal-title":"Annu Rev Immunol"},{"key":"2652_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05705-7","volume":"22","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Bai X, Guo S, Zhang X, Liu J, Zhao M, et al. Efficacy and safety of CAR-T therapy targeting CLL1 in patients with extramedullary diseases of acute myeloid leukemia. J Transl Med. 2024;22:888.","journal-title":"J Transl Med"},{"key":"2652_CR46","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1016\/S2352-3026(22)00378-7","volume":"10","author":"DA Sallman","year":"2023","unstructured":"Sallman DA, Kerre T, Havelange V, Poire X, Lewalle P, Wang ES, et al. CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial. Lancet Haematol. 2023;10:e191\u2013e202.","journal-title":"Lancet Haematol"},{"key":"2652_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26683-0","volume":"12","author":"N El Khawanky","year":"2021","unstructured":"El Khawanky N, Hughes A, Yu W, Myburgh R, Matschulla T, Taromi S, et al. Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia. Nat Commun. 2021;12:6436.","journal-title":"Nat Commun"},{"key":"2652_CR48","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1038\/leu.2016.373","volume":"31","author":"S Rafiq","year":"2017","unstructured":"Rafiq S, Purdon TJ, Daniyan AF, Koneru M, Dao T, Liu C, et al. Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen. Leukemia. 2017;31:1788\u201397.","journal-title":"Leukemia"},{"key":"2652_CR49","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/j.jcyt.2024.06.010","volume":"26","author":"H He","year":"2024","unstructured":"He H, Vedia RA, Lu S, Li Q, Cox KR, St John L, et al. Hu8F4-CAR T cells with mutated Fc spacer segment improve target specificity and mediate anti-leukemia activity in vivo. Cytotherapy. 2024;26:1331\u201340.","journal-title":"Cytotherapy"},{"key":"2652_CR50","doi-asserted-by":"publisher","first-page":"176ra133","DOI":"10.1126\/scitranslmed.3005661","volume":"5","author":"T Dao","year":"2013","unstructured":"Dao T, Yan S, Veomett N, Pankov D, Zhou L, Korontsvit T, et al. Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. Sci Transl Med. 2013;5:176ra133.","journal-title":"Sci Transl Med"},{"key":"2652_CR51","doi-asserted-by":"publisher","first-page":"4262","DOI":"10.1182\/blood-2010-07-299248","volume":"117","author":"A Sergeeva","year":"2011","unstructured":"Sergeeva A, Alatrash G, He H, Ruisaard K, Lu S, Wygant J, et al. An anti-PR1\/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells. Blood. 2011;117:4262\u201372.","journal-title":"Blood"},{"key":"2652_CR52","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.4049\/jimmunol.0902414","volume":"184","author":"B Verma","year":"2010","unstructured":"Verma B, Neethling FA, Caseltine S, Fabrizio G, Largo S, Duty JA, et al. TCR mimic monoclonal antibody targets a specific peptide\/HLA class I complex and significantly impedes tumor growth in vivo using breast cancer models. J Immunol. 2010;184:2156\u201365.","journal-title":"J Immunol"},{"key":"2652_CR53","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.copbio.2009.10.011","volume":"20","author":"WR Strohl","year":"2009","unstructured":"Strohl WR. Optimization of Fc-mediated effector functions of monoclonal antibodies. Curr Opin Biotechnol. 2009;20:685\u201391.","journal-title":"Curr Opin Biotechnol"},{"key":"2652_CR54","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ymeth.2005.01.001","volume":"36","author":"WY Hwang","year":"2005","unstructured":"Hwang WY, Foote J. Immunogenicity of engineered antibodies. Methods. 2005;36:3\u201310.","journal-title":"Methods"},{"key":"2652_CR55","doi-asserted-by":"publisher","first-page":"5476","DOI":"10.4049\/jimmunol.1201221","volume":"189","author":"G Alatrash","year":"2012","unstructured":"Alatrash G, Mittendorf EA, Sergeeva A, Sukhumalchandra P, Qiao N, Zhang M, et al. Broad cross-presentation of the hematopoietically derived PR1 antigen on solid tumors leads to susceptibility to PR1-targeted immunotherapy. J Immunol. 2012;189:5476\u201384.","journal-title":"J Immunol"},{"key":"2652_CR56","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1158\/0008-5472.CAN-11-4135","volume":"72","author":"EA Mittendorf","year":"2012","unstructured":"Mittendorf EA, Alatrash G, Qiao N, Wu Y, Sukhumalchandra P, St John LS, et al. Breast cancer cell uptake of the inflammatory mediator neutrophil elastase triggers an anticancer adaptive immune response. Cancer Res. 2012;72:3153\u201362.","journal-title":"Cancer Res"},{"key":"2652_CR57","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1158\/2326-6066.CIR-16-0141","volume":"5","author":"HL Peters","year":"2017","unstructured":"Peters HL, Tripathi SC, Kerros C, Katayama H, Garber HR, St John LS, et al. Serine proteases enhance immunogenic antigen presentation on lung cancer cells. Cancer Immunol Res. 2017;5:319\u201329.","journal-title":"Cancer Immunol Res"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02652-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02652-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02652-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T18:25:21Z","timestamp":1757183121000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02652-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":57,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["2652"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02652-0","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,28]]},"assertion":[{"value":"16 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All procedures were conducted in compliance with the laboratory research guidelines and regulations of the University of Texas MD Anderson Cancer Center. The research was approved under the MD Anderson IRB-approved tissue collection protocol (Protocol# LAB99-062) and the IACUC-approved animal protocol (Protocol# 00001336-RN02). Informed consent was obtained from all participants prior to tissue collection. This study did not involve direct research on human subjects but used archived human tissue samples. No identifiable images of human participants are included in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}